Key Points

• Axsome Therapeutics has launched exciting new drugs over the past year, and they are delivering growth.

• The biopharma player’s late-stage pipeline could translate into additional products over the next few years.

Axsome Therapeutics (NASDAQ:AXSM) has seen its stock price climb over the past few years -- and for good reason. The company has progressively launched new products, confirming its expertise in the neuroscience space. This biotech aims to treat a variety of conditions linked to central nervous system (CNS) operations, from depression to migraine and narcolepsy.

All of this helped the stock advance 180% over three years, as investors got excited about new product approvals, pipeline progress, and double-digit revenue growth. But, in recent times, Axsome shares have pulled back, falling about 15% over the past three months. Is it too late to get in on this hot healthcare stock -- or is it a buy on the dip? Let's find out.

Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger. Most investors think they missed the AI boat because they didn't buy Nvidia in 2005. But according to our analysts, we’re only at the end of "Act 1"—the R&D phase. "Act 2" is the global rollout. Continue »

Image source: Getty Images.

A central nervous system specialist

First, let's consider Axsome's story so far. The biopharma company specializes in CNS conditions and is targeting several through currently marketed products as well as candidates in the pipeline. The company has three commercialized drugs, starting with its lead product, Auvelity, approved for major depressive disorder in 2022 and, more recently, approved for agitation associated with Alzheimer's disease. That drug's sales jumped more than 50% in the recent quarter to about $180 million, and it's making important progress in the Alzheimer's agitation indication.

Auvelity launched into the Alzheimer's market in June, and in the first eight weeks to follow, new-to-brand prescriptions among adults ages 65 and older increased 126% compared with the same period in the previous quarter. So the Alzheimer's indication immediately broadened the drug's revenue opportunity. And the number of Auvelity prescriptions written in the quarter, up 34% year-over-year to 266,000, confirms this.

Meanwhile, Sunosi, the company's treatment for excessive daytime sleepiness associated with narcolepsy or sleep apnea, saw a 14% year-over-year increase in prescriptions to 61,000. And that drug generated net product revenue, including product sales and royalties, of more than $35 million.

Finally, Symbravo, a migraine treatment that launched in June of last year, saw a 30% increase in prescriptions from the first quarter to 23,500. And sales surged more than 400% to $2.3 million. It's important to note that Symbravo is in the early stages of its growth story, as payer coverage is at 57% -- there's room for expansion -- and the company is completing additions to its Symbravo sales force. A larger sales force will help the company reach further into the primary care and specialist communities.

Five phase 3 programs

While these three drugs are powering revenue growth, Axsome isn't sitting still. The company has five phase 3 programs -- in attention deficit and hyperactivity disorder, major depressive disorder, binge eating disorder, shift work disorder, and fibromyalgia -- ongoing. And Axsome is awaiting a regulatory decision on its narcolepsy candidate -- regulators are expected to decide by May of next year. All of this suggests new revenue drivers may be near.

So, a lot is going on at Axsome, and these recent launches and late-stage trials could lead to significant growth over the next few years. This means now could be a very exciting time to own Axsome stock.

But, is it too late to buy? No -- this story is just beginning, and potential catalysts of revenue growth and product approvals could push the stock higher in the quarters to come. Meanwhile, the fact that Axsome has three commercialized products generating revenue makes it less of a risky bet than a company without products on the market. And Axsome recently said that it expects its current cash to fund operations into cash flow positivity. This is another element that lowers risk for shareholders.

So, when you buy Axsome stock, you're getting in on an innovative biopharma company -- something growth investors like -- but the company also offers you elements of safety, such as a portfolio of revenue-generating products and a healthy financial picture. This makes it a stock cautious investors may consider too.

All of this means that Axsome is a great stock to buy today on the dip -- and hold onto as new and possibly future drugs drive growth.

Should you buy stock in Axsome Therapeutics right now?

Before you buy stock in Axsome Therapeutics, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Axsome Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $412,074!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,314,319!*

Now, it’s worth noting Stock Advisor’s total average return is 932% — a market-crushing outperformance compared to 209% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

*Stock Advisor returns as of September 18, 2026.

Adria Cimino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Axsome Therapeutics. The Motley Fool has a disclosure policy.

Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.